EE05581B1 - Aripiprasooli ravimlahus peroraalseks manustamiseks - Google Patents

Aripiprasooli ravimlahus peroraalseks manustamiseks

Info

Publication number
EE05581B1
EE05581B1 EEP200300523A EEP200300523A EE05581B1 EE 05581 B1 EE05581 B1 EE 05581B1 EE P200300523 A EEP200300523 A EE P200300523A EE P200300523 A EEP200300523 A EE P200300523A EE 05581 B1 EE05581 B1 EE 05581B1
Authority
EE
Estonia
Prior art keywords
oral
aripiprazole
solution
oral administration
administration
Prior art date
Application number
EEP200300523A
Other languages
English (en)
Inventor
Parab Prakash
Chou Joyce
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05581(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200300523A publication Critical patent/EE200300523A/et
Publication of EE05581B1 publication Critical patent/EE05581B1/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
EEP200300523A 2001-04-25 2002-04-24 Aripiprasooli ravimlahus peroraalseks manustamiseks EE05581B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28671801P 2001-04-25 2001-04-25
PCT/US2002/013048 WO2002085366A1 (en) 2001-04-25 2002-04-24 Aripiprazole oral solution

Publications (2)

Publication Number Publication Date
EE200300523A EE200300523A (et) 2004-02-16
EE05581B1 true EE05581B1 (et) 2012-10-15

Family

ID=23099862

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300523A EE05581B1 (et) 2001-04-25 2002-04-24 Aripiprasooli ravimlahus peroraalseks manustamiseks

Country Status (37)

Country Link
US (1) US6977257B2 (et)
EP (2) EP2436384B2 (et)
JP (1) JP4401077B2 (et)
KR (1) KR100909329B1 (et)
CN (1) CN1512884B (et)
AR (1) AR033168A1 (et)
AT (1) ATE537831T1 (et)
AU (1) AU2002254722B2 (et)
BG (1) BG66177B1 (et)
BR (1) BR0208986A (et)
CA (1) CA2445276C (et)
CY (1) CY1112606T1 (et)
CZ (1) CZ306181B6 (et)
DK (1) DK1381367T3 (et)
EE (1) EE05581B1 (et)
ES (1) ES2377855T3 (et)
GE (1) GEP20053602B (et)
HK (2) HK1058316A1 (et)
HR (1) HRP20030870B1 (et)
HU (1) HU230456B1 (et)
IL (2) IL158202A0 (et)
IS (1) IS2863B (et)
MX (1) MXPA03009728A (et)
MY (1) MY129350A (et)
NO (1) NO324606B1 (et)
NZ (1) NZ528550A (et)
PE (1) PE20021086A1 (et)
PL (1) PL206882B1 (et)
PT (1) PT1381367E (et)
RS (1) RS52082B (et)
RU (1) RU2295960C2 (et)
SK (1) SK287948B6 (et)
TW (1) TWI337865B (et)
UA (1) UA76144C2 (et)
UY (1) UY27273A1 (et)
WO (1) WO2002085366A1 (et)
ZA (1) ZA200307797B (et)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
TWI307626B (en) * 2002-08-20 2009-03-21 Bristol Myers Squibb Co Aripiprazole complex formulation and method
ES2373042T3 (es) * 2003-10-08 2012-01-30 Mallinckrodt Llc Solución de metilfenidato y procedimientos de administración y producción asociados.
DE602004017342D1 (de) * 2003-10-23 2008-12-04 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
EP1708680A2 (en) * 2004-01-21 2006-10-11 Janssen Pharmaceutica N.V. Mitratapide oral solution
JP2009508859A (ja) 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
ATE429906T1 (de) * 2006-01-05 2009-05-15 Teva Pharma Trockene aripiprazolformulierungen
EP2036545A1 (en) * 2006-01-05 2009-03-18 Teva Pharmaceutical Industries Ltd. Aripiprazole tablets
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
US20100021891A1 (en) * 2006-06-12 2010-01-28 Bernard Lerer Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
NZ582415A (en) 2007-07-31 2012-05-25 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
SG172361A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside analogs
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8815261B2 (en) * 2009-06-19 2014-08-26 Medrx Co., Ltd. Composition for external application comprising aripiprazole and organic acid as active ingredients
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
EP2752422B1 (en) 2010-03-31 2017-08-16 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
WO2011123672A1 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
RU2757859C2 (ru) 2011-03-18 2021-10-21 Алкермес Фарма Айэленд Лимитед Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбитана
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
GB2505860B (en) * 2011-06-27 2018-10-31 Shanghai Zhongxi Pharmaceutical Corp Aripiprazole medicament formulation and preparation method therefor
CN102846616B (zh) * 2011-06-27 2015-05-06 上海中西制药有限公司 一种阿立哌唑制剂及其制备方法
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
EP2868319A4 (en) * 2012-06-29 2016-02-24 Maruishi Pharma ORAL PHARMACEUTICAL PREPARATION OF ARIPIPRAZOLE
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN104736142B (zh) * 2012-09-26 2020-03-03 百时美-施贵宝控股爱尔兰无限公司 阿哌沙班液体制剂
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
WO2014059363A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals Llc Oral solution formulations of aripiprazole
WO2014060324A1 (en) * 2012-10-16 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S Aripiprazole formulations
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
EP3119399A4 (en) 2014-03-20 2017-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) * 2015-06-12 2016-12-07 高田製薬株式会社 アリピプラゾール含有内用液剤
WO2017025930A1 (en) * 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CN108434146A (zh) * 2017-02-16 2018-08-24 天津国际生物医药联合研究院 一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 阿立哌唑口服溶液及其制备方法
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN112666267B (zh) * 2019-10-15 2023-09-26 上海上药中西制药有限公司 一种阿立哌唑药品有关物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU843739A3 (ru) 1978-02-17 1981-06-30 Карл Томэ Гмбх (Фирма) Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja) 1982-09-29 1984-04-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体−シクロデキストリン包接化合物
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5457099A (en) 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
TW254855B (et) 1993-07-28 1995-08-21 Otsuka Pharma Co Ltd
CN1252003A (zh) * 1997-03-31 2000-05-03 强生消费者公司 增强药物化合物渗透作用的溶剂系统
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
CA2342844A1 (en) * 1998-09-03 2000-03-16 Robert D. Kross Freeze-resistant topical germicides and methods related thereto
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation

Also Published As

Publication number Publication date
CZ306181B6 (cs) 2016-09-14
US6977257B2 (en) 2005-12-20
GEP20053602B (en) 2005-08-10
EP1381367B1 (en) 2011-12-21
SK12642003A3 (sk) 2004-07-07
YU84703A (sh) 2006-08-17
TWI337865B (en) 2011-03-01
UA76144C2 (uk) 2006-07-17
RU2295960C2 (ru) 2007-03-27
CA2445276C (en) 2009-10-13
HU230456B1 (hu) 2016-07-28
HUP0303946A2 (hu) 2004-04-28
HRP20030870A2 (en) 2004-06-30
CA2445276A1 (en) 2002-10-31
NO324606B1 (no) 2007-11-26
HRP20030870B1 (en) 2011-10-31
ES2377855T3 (es) 2012-04-02
PL206882B1 (pl) 2010-10-29
BR0208986A (pt) 2004-04-20
RU2003132426A (ru) 2005-04-20
EE200300523A (et) 2004-02-16
EP2436384B1 (en) 2015-06-10
EP1381367A4 (en) 2009-07-01
PE20021086A1 (es) 2002-12-14
UY27273A1 (es) 2002-11-29
MXPA03009728A (es) 2004-01-29
EP1381367A1 (en) 2004-01-21
JP4401077B2 (ja) 2010-01-20
CN1512884A (zh) 2004-07-14
MY129350A (en) 2007-03-30
AU2002254722B2 (en) 2006-11-09
US20020193438A1 (en) 2002-12-19
DK1381367T3 (da) 2012-04-10
IL158202A0 (en) 2004-05-12
CZ20032821A3 (cs) 2004-09-15
NZ528550A (en) 2005-03-24
PL364666A1 (en) 2004-12-13
CY1112606T1 (el) 2016-02-10
ZA200307797B (en) 2004-10-06
NO20034705L (no) 2003-11-28
KR100909329B1 (ko) 2009-07-24
EP2436384A3 (en) 2012-09-19
IS2863B (is) 2013-12-15
KR20030096332A (ko) 2003-12-24
NO20034705D0 (no) 2003-10-21
EP2436384A2 (en) 2012-04-04
JP2004532225A (ja) 2004-10-21
IS6994A (is) 2003-10-14
IL158202A (en) 2008-04-13
BG66177B1 (bg) 2011-11-30
HK1058316A1 (en) 2004-05-14
ATE537831T1 (de) 2012-01-15
CN1512884B (zh) 2010-05-26
BG108216A (bg) 2004-12-30
HUP0303946A3 (en) 2005-06-28
RS52082B (sr) 2012-06-30
WO2002085366A1 (en) 2002-10-31
AR033168A1 (es) 2003-12-03
SK287948B6 (sk) 2012-06-04
HK1168792A1 (en) 2013-01-11
PT1381367E (pt) 2012-03-01
EP2436384B2 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
EE05581B1 (et) Aripiprasooli ravimlahus peroraalseks manustamiseks
NO20033556L (no) Farmasöytiske formuleringer
NO20033384D0 (no) Farmasöytisk formulering
NO20033815D0 (no) Farmasöytiske salter
EE200300416A (et) Ravimvorm
NO20040125L (no) Enterale formuleringer
DE50201898D1 (de) Inhalationskapseln
NO20035627D0 (no) Farmasöytisk formulering
NO20035315D0 (no) Farmasöytiske kombinasjoner
DE50209245D1 (de) Neuroprotektives medikament
NO20034556L (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
NO20043007L (no) Farmasoytisk suspensjon for oral administrering
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
NO20041236L (no) Farmasoytisk formulering
DK1330280T3 (da) Lægemiddelinhalator
SE0102823D0 (sv) New drug
SE0103116D0 (sv) Pharmaceutical combination
SE0103565D0 (sv) Pharmaceutical formulation
SE0102957D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
SE0102069D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation
SE0101171D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
MM4A Lapsed by not paying the annual fees

Effective date: 20190424